Mineralocorticoid Receptor Antagonists in End Stage Renal Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 118 participants.

Also called NCT01691053

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 118 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01691053
  • EudraCT 2011-003179-12
Other papers using this trial's data
  • The effect of spironolactone on diastolic function in haemodialysis patients The international journal of cardiovascular imaging, 2021-06 DOI, PubMed 33544240, PMC8255262 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Germany (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01691053. Randomized; quadruple masking; primary purpose treatment. Start 2012-12 (registry gives no type); primary completion 2017-02-14 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Mineralocorticoid Receptor Antagonists in End Stage Renal Disease
Acronym
MiREnDa
Condition
End Stage Renal Disease / Hemodialysis
Intervention (Drug)
Spironolactone
Intervention (Drug)
Placebo
Lead sponsor
Wuerzburg University Hospital (class: other)
Collaborator
German Federal Ministry of Education and Research (class: other government)
Collaborator
Clinical Trial Center Wuerzburg (CTCW) (class: not stated)

Record details

Record id
cardio:ct-nct01691053
Content hash
bafc89604a21d098288fed570325c3e1933ad70dcc3bd199bd95754bbfcca97f